linjc16/ctgov huggingface dataset:
Effect of Semi-sitting Position on Mask Ventilation

Study Overview
=================
Brief Summary
-----------------
We compare the effect on semi-sitting position on mask ventilation in anesthetized and paralyzed obese patients

Official Title
-----------------
Effect of Semi-sitting Position on Mask Ventilation in Anesthetized and Paralyzed Patients

Conditions
-----------------
Ventilation

Intervention / Treatment
-----------------
* Other: patient position


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obese patients undergoing general anesthesia Exclusion Criteria: diseases or structural abnormalities in the upper airway those who were at risk of aspiration cardiovascular or respiratory diseases pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Supine position<br>After the induction of anesthesia, mask ventilation is performed in the supine position. | Other: patient position<br>* After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.<br>|
| Experimental: Semi-sitting position<br>After the induction of anesthesia, mask ventilation is performed in the semi-sitting position. | Other: patient position<br>* After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expiratory tidal volume | Expiratory tidal volume is assessed during mask ventilation in the supine and semi-sitting positions. | 1 minute after the induction of anesthesia | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Minute ventilation during mask ventilation in the supine and semi-sitting positions | Minute ventilation is assessed during mask ventilation | 1 minute after anesthesia induction | 
| The incidence of inadequate mask ventilation or dead space ventilation. | The incidence of inadequate mask ventilation or dead space ventilation is recorded. | during mask ventilation | 
| Peak inspiratory pressure | Peak inspiratory pressure is recorded. | during mask ventilation |
An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers

Study Overview
=================
Brief Summary
-----------------
Patient interviews to evaluate the reason patients discontinue biologic therapy and/or fail to follow up with provider.

Detailed Description
-----------------
Retrospective chart review and patient interviews to evaluate the reason patients discontinue biologic therapy and/or fail to follow up with provider. This research intends to improve the continuity of care by determining why patients stop therapy and what can be done to improve their experience with the provider, pharmaceutical companies and specialty pharmacies.

Official Title
-----------------
An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Drug: Biologic Agent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female adults ≥ 18 years of age. Was receiving first or second biologic therapy Has not had a follow up with treating physician in ≥ 9 months Exclusion Criteria: Actively receiving biologic therapy Was not receiving first or second biologic therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Biologic Therapy<br>Patient's who received and discontinued a biologic therapy | Drug: Biologic Agent<br>* Patients who discontinued a bioloic agent<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the most common reason for discontinuation | Tally number of patients who discontinued due to adverse events, insurance issues or category other. | 5 years |
Sedation During Pediatric Diagnostic Gastrointestinal Endoscopy Gastrointestinal Endoscopy

Study Overview
=================
Brief Summary
-----------------
comparison between propofol-fentanyl and propofol-ketamine for sedation in pediatric diagnostic gastrointestinal endoscopy.

Detailed Description
-----------------
It is a prospective double blinded controlled study that will be carried out on 60 pediatric patients undergoing GIT endoscopy; they will be divided into two groups of 30 patients each:- Group I (PF): will receive 0.5 µg/ kg fentanyl + 2 mg/ kg propofol IV. Group II (KF): will receive Ketofol (1 ketamine: 4 propofol) 0.5 mg/kg ketamine + 2 mg/kg propofol IV.

Official Title
-----------------
Propofol-Ketamine vs. Propofol-Fentanyl for Sedation During Pediatric Diagnostic Gastrointestinal Endoscopy

Conditions
-----------------
Sedation

Intervention / Treatment
-----------------
* Drug: Fentanyl
* Drug: Ketamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric patients undergoing diagnostic GIT endoscopy ASA I-II Exclusion Criteria: Emergency endoscopy Respiratory infection and hyperactive airways History of serious adverse effects related to anesthetics (e.g. allergic reactions), a family history of reactions to the study drugs Morbid obesity, and neuropsychiatric disorders

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Fentanyl<br>Group I (FP): will receive 0.5 µg/ kg fentanyl + 2 mg/ kg propofol IV. | Drug: Fentanyl<br>* fentanyl used with propofol for sedation<br>* Other names: Fentanyl Citrate;|
| Active Comparator: Ketamine<br>Group II (KP): will receive 0.5 mg/kg ketamine + 2 mg/kg propofol IV. | Drug: Ketamine<br>* ketamine used with propofol for sedation<br>* Other names: katalar;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of desaturation | when oxygen saturation below 90% | up to 2 days after operation |
A Real-time and Computerized Sonographic Reporting System in Predicting Malignant Cervical Lymphadenopathy

Study Overview
=================
Brief Summary
-----------------
The investigaotors want to establish a real-time and computerized score reporting system based on the significant predictors of the measured sonographic parameters and demographic data.

Detailed Description
-----------------
One hundred eight patients with neck lymphadenopathy, receiving ultrasonography and ultrasound-guided fine-needle aspiration (US-FNA), were used to construct a predictive model. This model was validated by another independent patient cohort.

Official Title
-----------------
A Real-time and Computerized Sonographic Scoring System for Predicting Malignant Cervical Lymphadenopathy

Conditions
-----------------
Lymphadenopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with previously untreated neck masses underwent neck US Exclusion Criteria: The neck mass was not lymph node No US-FNA cytology result

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 83 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neck masses<br>Patients with previously untreated neck masses | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The final diagnoses of lymph nodes were made by US-FNA cytological studies, pathologic results of the biopsy specimens, or at least 3 months of negative follow-up observations. |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
age, lymphadenopathy, fine needle aspiration, sonography
A Reduced 11-b-HSD Activity, a Novel Mechanism of Salt Sensitivity and Hypertension After Renal Allograft Donation?

Study Overview
=================
Brief Summary
-----------------
Consecutive living-kidney donor candidates (n=100) will be recruited after being accepted for donation according to official guidelines. An assessment of salt sensitivity, 11 beta HSD activity, 24 hour blood pressure, urine collection and physical exam will be performed prior nephrectomy and 14, 52, 156, 208 days post-nephrectomy.

Detailed Description
-----------------
Consecutive living-kidney donor candidates (n=100) will be recruited after being accepted for donation. The assessment of salt sensitivity, 11 beta HSD activity, 24 hour blood pressure, urine collection and physical exam will be performed prior nephrectomy and 14, 52, 156, 208 days post-nephrectomy.

Official Title
-----------------
A Reduced 11 Beta Hydroxysteroid Dehydrogenase 2 (11 Beta HSD2) Activity, a Novel Mechanism of Salt Sensitivity and Hypertension After Renal Allograft Donation?

Conditions
-----------------
Renal Failure, Renal Transplantation, Living Donors

Intervention / Treatment
-----------------
* Dietary Supplement: Low and high salt diets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acceptance for living kidney donation Exclusion Criteria: withdrawal of consent

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br> | Dietary Supplement: Low and high salt diets<br>* High salt diet: 150mmol/d Low salt diet: 30mmol/d<br>* Other names: NaCl;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Salt sensitivity, arterial hypertension |  | day 0, 14, 52, 156, 208, yearly |
Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to better understand brain function and psychiatric and neurological illness when taking Invega or Risperdal. The objective is to compare the brain effects of Invega to Risperdal in patients with Schizophrenia. This comparison will be evaluated with PET imaging, fMRI, and neurological ratings and assessments.

Official Title
-----------------
Contrasting the Brain Effects of Risperidone and Invega With fMRI and PET Scanning

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Risperidone
* Drug: Paliperidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: are currently taking Risperdal and have been on the medication for at least three weeks are diagnosed with schizophrenia are able to provide written informed consent can safely have an MRI Exclusion Criteria: are treatment resistant or intolerant to Risperdal have participated in another drug study in the past 28 days are pregnant or trying to become pregnant or are breastfeeding are colorblind have a history of alcohol, cannabis, or cocaine abuse within two weeks prior to the study have a current or past history of a major medical illness or have abnormal lab values which the study doctor feels is significant certain medications are also exclusionary including aripiprazole.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Risperdal<br>Risperdal 2-8mg per day | Drug: Risperidone<br>* 2mg - 8mg per day, for the duration of participation in the study<br>* Other names: Risperdal;|
| Experimental: Invega<br>Invega 6-12mg per day | Drug: Paliperidone<br>* 6mg - 12mg per day, for the duration of participation in the study<br>* Other names: Invega;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of BOLD signal activation and FDG metabolism of the DLPFC, superior temporal gyrus and amygdala, and their interaction between Invega and Risperdal |  | approximately 6-10 weeks |
Tinnitus Treatment Using a Smartphone Application

Study Overview
=================
Brief Summary
-----------------
People with tinnitus will use a smartpphone app in which they are instructed to reject maladaptive thoughts by throwing them away from themselves (upwards) and embrace supportive thoughts by pulling them towards themselves (downwards). The Tinnitus Handicap Inventory will be used to measure the effect of the application.

Official Title
-----------------
The Use of a Smartphone Application for Tinnitus Treatment

Conditions
-----------------
Tinnitus, Subjective

Intervention / Treatment
-----------------
* Behavioral: Tinnitus application


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tinnitus lasting more than 3 months Exclusion Criteria: Brain space occupying lesion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br> | Behavioral: Tinnitus application<br>* Use of tinnitus application<br>|
| Other: Wait list<br> | Behavioral: Tinnitus application<br>* Use of tinnitus application<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tinnitus Handicap Inventory score | The Tinnitus Handicap Inventory measures the degree of disturbance the tinnitus causes the patients, on a a total scale of 0-100. 0 is the lowest possible score (no disturbance caused by the tinnitus, 100- the most severe form of intrusiveness) | 34 days |
Bicuspid Aortic Valve (BAV) Registry

Study Overview
=================
Brief Summary
-----------------
The purpose of this registry is to gather information on patients with bicuspid aortic valve disease.

Detailed Description
-----------------
The purpose of this registry is to gather information on patients with bicuspid aortic valve disease. The data collected in the registry will be used to assess patterns of aortic dilation, responses to medical therapy based on serial imaging and to assess for potential genetic markers of this disease

Official Title
-----------------
Bicuspid Aortic Valve and Ascending Aortic Aneurysm Registry

Conditions
-----------------
Bicuspid Aortic Valve

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient over the age of 18 who is able/willing to give informed consent with the diagnosis of bicuspid aortic valve disease, a family history of this disease or an ascending aortic aneurysm that is idiopathic can be included in the registry. Exclusion Criteria: Patients unable or unwilling to give informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bicuspid Aortic Valve Disease Patients<br>Patients with the diagnosis of BAV disease. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterizing patients with bicuspid aortic valve disease | Identifying patients with bicuspid aortic valve disease, assessing the effect of medical intervention. | 30 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BAV, Bicuspid Aortic Valve Disease, Bicuspid Aortic Valve
Effect of Epidural Opioid Administered in the First A Period on the Progress of Labour

Study Overview
=================
Brief Summary
-----------------
Epidural anesthesia is used to relieve labour pain which helps reduce labour stress, increase comfort and improve cooperation with medical personnel. Administering opioid into the epidural space before cervical dilation of 4cm in the primigravida or 3cm in the multiparous can effectively reduce the pain levels with no effect on the labour progress. The aim of the study is to compare different opioids administered in this early labour stage.

Official Title
-----------------
Effect of Epidural Opioid Administered in the First A Period on the Progress of Labour

Conditions
-----------------
Anesthesia, Epidural, Opioid, Labor Pain

Intervention / Treatment
-----------------
* Drug: Fentanyl
* Drug: Sufentanil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: parturient in labour without cervical dilation and regular uterine contractions Exclusion Criteria: no consent known allergy to administered opioid contraindications to epidural analgesia coagulopathies including platelet count of less than 100,000 spine surgery in past

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Fentanyl<br>100mcg Fentanyl administered into epidural space during regular contractions before cervical dilation | Drug: Fentanyl<br>* 100mcg Fentanyl<br>|
| Active Comparator: Sufentanyl<br>10mcg sufentanyl administered into the epidural space during regular contractions before cervical dilation | Drug: Sufentanil<br>* 10mcg sufentanil<br>|
| No Intervention: Control<br>No epidural analgesia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity according to Numerical Rating Scale (NRS) | till 4cm cervical dilation in primigravida or 3cm multiparous | up to 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fetal heart rate | till 4cm cervical dilation in primigravida or 3cm multiparous | up to 24 hours | 
| Blood pressure parturient | till 4cm cervical dilation in primigravida or 3cm multiparous | up to 24 hours | 
| Heart rate of parturient | till 4cm cervical dilation in primigravida or 3cm multiparous | up to 24 hours |
Impact of Sleep Disruption on the Menstrual Cycle

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether sleep disruption affects menstrual cycle timing

Detailed Description
-----------------
Menstrual cycle dynamics were studied after sleep disruption

Official Title
-----------------
Impact of Sleep Disruption on the Menstrual Cycle

Conditions
-----------------
Sleep, Circadian Rhythm, Menstrual Cycle

Intervention / Treatment
-----------------
* Behavioral: Disrupting or changing the timing or the duration of sleep


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Regular menstrual cycles Exclusion Criteria: No medications affecting the menstrual cycle or sleep

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Luteal<br> | Behavioral: Disrupting or changing the timing or the duration of sleep<br>* Disrupting or changing the timing or the duration of sleep<br>|
| Follicular<br> | Behavioral: Disrupting or changing the timing or the duration of sleep<br>* Disrupting or changing the timing or the duration of sleep<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sleep, Circadian rhythms, Menstrual cycle